Beta-Blocker Selection: Which One, When, and Why It Matters

A 58-year-old woman comes back to clinic frustrated. Her primary care doctor started her on atenolol for blood pressure five years ago. When she developed atrial fibrillation last year, the cardiologist on call switched her to metoprolol tartrate twice a day. Six months later, after an echocardiogram showed an ejection fraction of 35 percent, she got a phone call telling her to stop the metoprolol tartrate and start metoprolol succinate XL once daily. Now she's on my schedule asking a reasonable question: "Why does it keep changing? Aren't they all the same drug?" The short answer is no. The longer answer is the point of this article.

I'm Dr. Damian Rasch, a cardiologist in Encinitas. Beta-blockers are one of the most prescribed drug classes in cardiology, and patients are often confused about why so many of them exist. Metoprolol succinate, metoprolol tartrate, carvedilol, bisoprolol, atenolol, propranolol, nebivolol, and labetalol all act on the same family of receptors, but they're not interchangeable. The right beta-blocker depends on what we're treating, what other conditions you have, and what we know from large clinical trials. This article walks through how beta-blockers work, why selection matters, and why your cardiologist may have switched you from one to another.

What Beta-Blockers Actually Do

Beta-blockers block adrenergic receptors. Your sympathetic nervous system uses adrenaline (epinephrine) and noradrenaline (norepinephrine) to speed up the heart, increase the force of each contraction, raise blood pressure, and prepare you for exertion. Beta-receptors are the docks where those signals land on heart muscle, blood vessels, lungs, kidneys, and other organs. When a beta-blocker sits in that dock, the signal can't land, and the downstream effects are blunted.

There are three main types of beta-receptors. Beta-1 receptors live mostly in the heart. Blocking them slows the heart rate, reduces the force of contraction, and lowers blood pressure. Beta-2 receptors live in the lungs, vascular smooth muscle, and elsewhere. Blocking them can constrict airways (a problem in asthma) and reduce vasodilation. Beta-3 receptors live in fat tissue and the bladder and matter less for cardiovascular drugs.

In cardiology, we use beta-blockers to slow the heart rate, reduce myocardial oxygen demand, suppress arrhythmias, lower blood pressure, and (in heart failure with reduced ejection fraction) reverse some of the harmful remodeling that catecholamines drive over time. The same drug can do different things at different doses and in different patients. That's part of why selection matters.

Beta-1 Selectivity: Cardioselective vs. Non-Selective

The first big distinction among beta-blockers is whether they're beta-1 selective (cardioselective) or non-selective. A cardioselective drug preferentially blocks beta-1 receptors at standard doses, leaving beta-2 receptors mostly alone. A non-selective drug blocks both.

The cardioselective beta-blockers commonly used in practice are metoprolol (both tartrate and succinate forms), bisoprolol, atenolol, and nebivolol. They tend to be better tolerated in patients with mild reactive airway disease because they spare the beta-2 receptors in the lungs. At low to moderate doses, they cause less bronchoconstriction than non-selective drugs.

The non-selective beta-blockers include propranolol, nadolol, and timolol. Carvedilol is also functionally non-selective, with the added feature of blocking alpha-1 receptors (causing some vasodilation). Labetalol is non-selective with alpha blockade as well.

Selectivity isn't absolute. At higher doses, even cardioselective drugs start to block beta-2 receptors. Patients with severe asthma can still have problems on metoprolol if the dose is high enough. The selectivity is a relative property, not an on/off switch. But for most patients, the distinction matters and shapes which drug we pick.

Heart Failure with Reduced Ejection Fraction: Only Three Choices

Here's a piece of cardiology that surprises many patients. For heart failure with reduced ejection fraction (HFrEF, an ejection fraction of 40 percent or lower), only three beta-blockers have been proven in large randomized trials to improve survival and reduce hospitalization. Those three are carvedilol, metoprolol succinate (the long-acting XL formulation), and bisoprolol. Every guideline in the United States, Europe, and beyond names the same three. They're not interchangeable with the other beta-blockers.

The evidence comes from a handful of landmark trials. MERIT-HF tested metoprolol succinate XL in nearly 4,000 patients with HFrEF and showed a 34 percent reduction in mortality. COPERNICUS tested carvedilol in patients with severe HFrEF and showed a 35 percent reduction in mortality, with benefits seen even in patients who were quite ill. CIBIS-II tested bisoprolol and showed a 34 percent mortality reduction. CAPRICORN extended carvedilol's benefit to patients post-myocardial infarction with reduced EF. These results, taken together, established that the right beta-blocker (started carefully and titrated up over weeks to months) saves lives in HFrEF.

What about other beta-blockers in HFrEF? Atenolol has not been proven to reduce mortality in HFrEF. Propranolol hasn't either. Nebivolol was studied in older patients with heart failure (the SENIORS trial) and showed a benefit, but the trial included patients with preserved EF as well, and the magnitude of benefit was smaller than the three guideline drugs. The bottom line: if you have HFrEF and you're on a beta-blocker, it should almost always be carvedilol, metoprolol succinate XL, or bisoprolol.

Why Succinate (XL) and Not Tartrate

Patients are often most confused by the metoprolol succinate vs. metoprolol tartrate distinction. They're both metoprolol, but they're not the same drug for our purposes. Metoprolol tartrate is the immediate-release form, dosed twice or three times a day, with peaks and troughs in blood level. Metoprolol succinate XL is the extended-release form, dosed once a day, with a much smoother concentration over 24 hours.

MERIT-HF studied metoprolol succinate XL. The trial was negative when run earlier with metoprolol tartrate (the MDC trial). The smoother pharmacokinetic profile of the XL form is thought to be why succinate works in HFrEF and tartrate doesn't have the same evidence base. So when I see a patient with HFrEF on metoprolol tartrate, I switch them. The conversion is roughly 1:1 by total daily dose (50 mg twice daily of tartrate becomes 100 mg once daily of succinate XL), with subsequent titration as tolerated.

Picking Among the Three

Carvedilol, metoprolol succinate, and bisoprolol all work in HFrEF. The choice depends on patient factors. Carvedilol's vasodilatory effect (from alpha-1 blockade) makes it useful in patients who also have hypertension. It's dosed twice daily, which some patients find inconvenient. Metoprolol succinate is once daily and tends to be well tolerated. Bisoprolol is once daily, highly beta-1 selective, and useful in patients with airway disease. Cost, dosing schedule, comorbidities, and prior tolerance shape the pick.

Hypertension: No Longer First-Line

For decades, beta-blockers were standard first-line therapy for hypertension. That's no longer the case. Current guidelines (ACC/AHA 2017, ESC, and others) recommend ACE inhibitors, ARBs, calcium channel blockers, and thiazide diuretics as first-line for most patients with hypertension. Beta-blockers are reserved for patients with specific indications: coronary artery disease, prior MI, heart failure, certain arrhythmias, or migraine prophylaxis.

The shift came largely from the LIFE trial, which compared losartan (an ARB) to atenolol (a beta-blocker) in patients with hypertension and left ventricular hypertrophy. Losartan reduced cardiovascular events and stroke compared to atenolol, despite similar blood pressure reductions. Subsequent meta-analyses suggested that atenolol-based therapy was less effective at preventing stroke than other antihypertensive classes. The cardiovascular community moved away from atenolol as a primary blood pressure drug, and beta-blockers in general lost their first-line status for uncomplicated hypertension.

Where do beta-blockers still belong in hypertension? In patients who need them anyway for another reason. If you have coronary disease, post-MI status, HFrEF, or rate-controlled AFib, the beta-blocker is doing multiple jobs at once, and your blood pressure benefits from it. As a standalone antihypertensive in someone without those indications, a beta-blocker isn't usually the first choice. Atenolol in particular has fallen out of favor for blood pressure alone.

Atrial Fibrillation: Rate Control

For rate control in atrial fibrillation, all beta-blockers work. The choice depends on comorbidities, dosing convenience, and what else the patient needs treated.

Metoprolol (tartrate or succinate), atenolol, and bisoprolol are common first picks for AFib rate control in patients without HFrEF. Metoprolol tartrate is dosed twice or three times a day and is useful when we want a more flexible up-and-down titration. Metoprolol succinate XL is once daily and tends to give smoother heart rate control across the day. Bisoprolol is once daily and well tolerated. Atenolol still works for rate control even if it's no longer favored for hypertension as a sole indication.

If the patient also has HFrEF, the choice narrows back to carvedilol, metoprolol succinate, or bisoprolol. Carvedilol works well for AFib rate control in patients with reduced EF, with the added benefit of survival improvement.

Sometimes a beta-blocker alone doesn't give adequate rate control during AFib, and we add a non-dihydropyridine calcium channel blocker (diltiazem or verapamil) or digoxin. The choice depends on EF, blood pressure, and exercise tolerance. Calcium channel blockers like diltiazem are avoided in HFrEF because they can worsen heart failure.

After a Heart Attack

Beta-blockers have a long-standing role after myocardial infarction. The BHAT trial in 1981 showed propranolol reduced mortality after MI. The COMMIT trial later showed metoprolol given early after MI reduced reinfarction and ventricular fibrillation, though early IV dosing in unstable patients can cause harm and must be done carefully.

In modern practice, beta-blockers are started after an MI in most patients (especially those with reduced EF) and continued long-term. The drug is usually metoprolol tartrate initially in the hospital (because it's easier to titrate), then often converted to metoprolol succinate XL or carvedilol on discharge. In patients with reduced EF after MI, carvedilol has the strongest evidence (CAPRICORN trial). For patients with normal EF after MI, the duration of therapy beyond the first year is debated, but most cardiologists continue beta-blockade indefinitely if it's well tolerated.

Specific Niches

Nebivolol

Nebivolol is a beta-1 selective beta-blocker with vasodilatory properties (mediated through nitric oxide release). Patients tend to report fewer cold extremities and less fatigue compared to older beta-blockers. It's a reasonable choice for patients who need beta-blockade but have struggled with side effects on metoprolol or atenolol. It hasn't replaced the three guideline drugs in HFrEF, but for hypertension or rate control with concern about peripheral side effects, nebivolol has a role.

Labetalol

Labetalol is a non-selective beta-blocker with alpha-1 blockade, used most often in pregnancy (where it's one of the preferred antihypertensives) and in hypertensive emergencies (given IV in monitored settings). The combined alpha and beta effect lowers blood pressure quickly without dropping cardiac output sharply. Outside those settings, it's less commonly used long-term.

Propranolol

Propranolol is the original beta-blocker and is still useful for several non-cardiac indications. It treats benign tremor, migraine prophylaxis, and performance anxiety (where its short-acting form blunts the physical symptoms of stage fright). In cardiology, it's used less often than metoprolol or carvedilol, but in patients who are already on it for tremor or migraine, we sometimes use that for blood pressure or rate control. It's non-selective, so it's avoided in active asthma.

COPD and Asthma Considerations

Patients with COPD or asthma often worry about beta-blockers. The concern is real but overstated for most patients. Cardioselective beta-blockers (metoprolol, bisoprolol, nebivolol) at standard doses are mostly safe in patients with COPD and well-controlled mild-to-moderate asthma. Multiple studies have shown that withholding beta-blockers from patients with COPD who have a cardiovascular indication causes more harm than the small risk of bronchospasm.

In severe or poorly controlled asthma, we're more cautious. Non-selective drugs (propranolol, nadolol, carvedilol) are usually avoided in active asthma because they can precipitate bronchospasm. If a patient with severe asthma has HFrEF and needs guideline-directed beta-blockade, bisoprolol (the most cardioselective of the three guideline drugs) is often the safest pick, started at low dose and titrated carefully with pulmonologist input.

If you have COPD or asthma and your cardiologist has prescribed a beta-blocker, the conversation worth having is which one and at what dose. The reflex of "no beta-blocker because of lung disease" is outdated for most patients, but the choice of agent and dose matters more than usual.

Side Effects

Beta-blockers have a predictable side effect profile, and knowing what to expect helps you tolerate them. The most common complaints are fatigue, exercise intolerance, cold hands and feet, sexual dysfunction (reduced libido or erectile dysfunction), bradycardia (slow heart rate, sometimes symptomatic), vivid dreams or sleep disturbance (more common with lipophilic drugs like propranolol and metoprolol that cross into the brain), masked symptoms of hypoglycemia in diabetics on insulin (the tremor and sweating that signal low blood sugar are blunted), and weight gain in some patients.

Many of these side effects are dose-dependent and improve with dose reduction. Some are drug-specific. Nebivolol tends to cause less of the cold-extremity and fatigue side effects. Carvedilol can cause more dizziness on standing because of its alpha-blocking vasodilator effect. Metoprolol succinate is well tolerated for most patients, but the lipophilic nature can produce dreams and fatigue.

If you're feeling miserable on your beta-blocker, that's worth a conversation. Sometimes we lower the dose. Sometimes we switch agents. Sometimes the issue is something else entirely (anemia, hypothyroidism, sleep apnea) and the beta-blocker is being blamed unfairly. Don't quietly tolerate a side effect that's reducing your quality of life. There's usually a way to improve it.

Stopping a Beta-Blocker: Don't Do It Abruptly

If you've been on a beta-blocker for more than a few weeks, your body has adapted to it. Your beta-receptors have upregulated (increased in number) to compensate for the blockade. If you stop the drug suddenly, those upregulated receptors are exposed to your normal adrenaline, and the result can be a rebound effect: rapid heart rate, elevated blood pressure, chest pain, and, in patients with coronary disease, a risk of myocardial infarction.

When we need to stop a beta-blocker, we do it gradually, usually over one to two weeks. We cut the dose in half, then in half again, then stop. This gives the body time to recalibrate. Patients who run out of their beta-blocker and stop cold should call us; we can usually bridge them with a short prescription or a partial dose to taper safely.

This rebound concern doesn't mean you're stuck on the drug forever. It just means stopping requires a plan, not an abrupt cutoff.

Why Your Dose Was Changed

Beta-blocker dosing isn't one-size-fits-all. We start low and titrate up based on tolerance, heart rate, blood pressure, and the indication. In HFrEF, the goal dose is the dose used in the landmark trials (carvedilol 25 mg twice daily, metoprolol succinate 200 mg daily, bisoprolol 10 mg daily), and reaching that dose is associated with better outcomes. Many patients can't tolerate the full target dose, but every step up matters.

Titration takes weeks to months. We typically increase the dose every two to four weeks if the patient is tolerating the current dose. Heart rate, blood pressure, and symptoms guide the pace. If you've been told your dose is going up, it's because we're trying to get you to the dose that does the most good. If your dose is going down, it's because the current dose is causing more side effects than benefit.

Patients sometimes assume that a higher dose means their heart is worse. That's not how to read it. Higher doses in HFrEF mean we're trying to give you the dose proven to save lives. Reaching the target is a goal, not a sign of decline.

Common Patient Questions

Why did my cardiologist switch me from metoprolol tartrate to metoprolol succinate?

Most likely because you have heart failure with reduced ejection fraction, or because once-daily dosing is more convenient and gives smoother heart rate control. Metoprolol tartrate (immediate release, twice or three times daily) and metoprolol succinate XL (extended release, once daily) are both metoprolol, but the XL form is the one with mortality benefit data in HFrEF. The conversion is roughly 1:1 by total daily dose.

Are all beta-blockers the same for AFib?

For pure rate control in AFib, all of them lower heart rate. The differences come from your other conditions. If you have HFrEF, we pick from the three guideline drugs. If you have asthma, we lean cardioselective. If you have hypertension, the beta-blocker can do double duty. The selection isn't random.

Can I drink coffee on a beta-blocker?

Usually yes, in moderation. Beta-blockers blunt the heart-rate response to caffeine, which is one reason patients on them tolerate caffeine better than they used to. Heavy caffeine intake can still cause palpitations and reflux issues, so moderation matters, but a morning cup of coffee is fine for most patients.

Will a beta-blocker make me too tired to exercise?

It might, especially in the first weeks after starting or after a dose increase. Beta-blockers blunt the heart-rate response to exercise, so the same workload feels harder at first. Most patients adjust within a few weeks. If you're an endurance athlete or use heart-rate-based training, your zones will shift and your peak heart rate will be lower. Talk to your cardiologist about training modifications. For most people, exercise tolerance returns to near baseline within a month.

Why is atenolol falling out of favor?

The LIFE trial and subsequent meta-analyses showed atenolol-based blood pressure therapy was less effective at preventing stroke than other antihypertensive classes, even at similar blood pressures. It's also renally cleared, which complicates dosing in kidney disease, and its half-life isn't as long as bisoprolol or metoprolol succinate, leading to peak-trough variation. For pure rate control or other indications, it's still useful. For hypertension as the sole indication, it's no longer first-line.

Can I take a beta-blocker if I have asthma?

Often yes, with a cardioselective drug at appropriate dose, if you have a cardiovascular indication that warrants it. The risk of bronchospasm with cardioselective drugs in well-controlled asthma is small, and the cardiovascular benefit is usually worth it. Severe or poorly controlled asthma changes the calculus, and we coordinate with your pulmonologist. Non-selective drugs (propranolol, carvedilol) are usually avoided in active asthma.

My pulse is in the 50s on my beta-blocker. Is that okay?

Often yes. A resting heart rate in the 50s on a beta-blocker is common and not a problem if you feel well. Concerns arise if you're getting symptomatic (lightheadedness, fatigue out of proportion to expectation, exercise intolerance) or if the heart rate is dropping into the 40s or lower. Bring the rate to your cardiologist's attention if you're symptomatic; otherwise, a low heart rate often reflects the medication doing what it's supposed to do.

Can I drink alcohol on a beta-blocker?

In moderation, yes. Alcohol can lower blood pressure and add to the dizziness some patients feel on beta-blockers, especially after standing up quickly. Heavy drinking is a problem for many reasons (it can trigger AFib, raise blood pressure long term, worsen heart failure), so moderation matters. A glass of wine with dinner on a beta-blocker is fine for most patients.

When to Escalate Care

Call 911 immediately for syncope (fainting) on a beta-blocker, severe shortness of breath at rest, chest pain that doesn't resolve with rest, or symptoms suggestive of stroke. A heart rate persistently below 40 with symptoms warrants urgent evaluation.

Contact your cardiologist the same day for new lightheadedness or dizziness on a beta-blocker, a heart rate consistently below 50 with fatigue, worsening shortness of breath, ankle swelling, or any sense that the medication is making you feel worse than the disease. Same-day phone evaluation lets us decide whether a dose adjustment or office visit is needed.

Schedule a clinic visit within one to two weeks for routine titration, side effect concerns that aren't urgent, questions about which drug you're on, or follow-up after a recent hospital discharge. Beta-blocker management is iterative; we expect to adjust over time.

A Final Note From Me

Beta-blockers are a family of drugs, not a single drug. The differences among them are real and matter for outcomes. The patient on atenolol for hypertension may be on a drug that's adequate but not the best choice for stroke prevention. The patient on metoprolol tartrate twice a day with HFrEF is on the right molecule but the wrong formulation for survival benefit. The patient on propranolol for tremor who develops AFib may need a different agent if HFrEF develops. Knowing why we picked the drug we picked, and why we sometimes change it, is part of being an informed partner in your own care.

If you're on a beta-blocker and you don't know why, that's a fair conversation to have at your next visit. There should be a clear indication, a clear target dose, and a clear plan for how long you're on it. If you're on a beta-blocker for hypertension alone and you don't have any of the cardiac indications that justify it, your primary care doctor or cardiologist may want to consider whether a different first-line agent makes more sense. If you're on metoprolol tartrate and you have HFrEF, the conversion to metoprolol succinate is straightforward and supported by trial data.

Beta-blocker selection is one of the small decisions in cardiology that adds up to better long-term outcomes. We don't always get it right on the first try, and patients sometimes need a couple of switches to find the agent and dose that works for their body and their disease. The right beta-blocker, at the right dose, in the right patient, is one of the most evidence-supported interventions we have. Getting there is worth the iteration.

References

1. MERIT-HF Study Group. "Effect of Metoprolol CR/XL in Chronic Heart Failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)." Lancet 353, no. 9169 (1999): 2001-2007.

2. Packer, Milton, Andrew J. S. Coats, Michael B. Fowler, et al. "Effect of Carvedilol on Survival in Severe Chronic Heart Failure." New England Journal of Medicine 344, no. 22 (2001): 1651-1658.

3. CIBIS-II Investigators and Committees. "The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A Randomised Trial." Lancet 353, no. 9146 (1999): 9-13.

4. Dargie, Henry J. "Effect of Carvedilol on Outcome after Myocardial Infarction in Patients with Left Ventricular Dysfunction: The CAPRICORN Randomised Trial." Lancet 357, no. 9266 (2001): 1385-1390.

5. Beta-Blocker Heart Attack Trial Research Group. "A Randomized Trial of Propranolol in Patients with Acute Myocardial Infarction. I. Mortality Results." JAMA 247, no. 12 (1982): 1707-1714.

6. Chen, Zhengming, Lixin Jiang, Yiping Chen, et al. "Addition of Clopidogrel to Aspirin in 45,852 Patients with Acute Myocardial Infarction: Randomised Placebo-Controlled Trial (COMMIT)." Lancet 366, no. 9497 (2005): 1607-1621.

7. Dahlof, Bjorn, Richard B. Devereux, Sverre E. Kjeldsen, et al. "Cardiovascular Morbidity and Mortality in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE): A Randomised Trial against Atenolol." Lancet 359, no. 9311 (2002): 995-1003.

8. Whelton, Paul K., Robert M. Carey, Wilbert S. Aronow, et al. "2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults." Journal of the American College of Cardiology 71, no. 19 (2018): e127-e248.

9. Heidenreich, Paul A., Biykem Bozkurt, David Aguilar, et al. "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure." Journal of the American College of Cardiology 79, no. 17 (2022): e263-e421.

10. Flather, Marcus D., Marcelo C. Shibata, Andrew J. S. Coats, et al. "Randomized Trial to Determine the Effect of Nebivolol on Mortality and Cardiovascular Hospital Admission in Elderly Patients with Heart Failure (SENIORS)." European Heart Journal 26, no. 3 (2005): 215-225.

Published on damianrasch.com. The above information was composed by Dr. Damian Rasch, drawing on individual insight and bolstered by digital research and writing assistance. The information is for educational purposes only and does not constitute medical advice.